Bukwang Unipharma Overview
- Year Founded
-
1956
- Status
-
Public
- Employees
-
131
- Stock Symbol
-
080720
- Share Price
-
$5.62
- (As of Wednesday Closing)
Bukwang Unipharma General Information
Description
Unionkorea Pharm Co Ltd is a pharmaceutical company. The company is engaged in the development, manufacturing and marketing of brain metabolism enhancer, prescription drugs, Anti-inflammatory analgesics, and skeletal muscle relaxants.
Contact Information
Website
www.bkup.co.krCorporate Office
- 240 Pangyoyeok-ro, Bundang-gu
- Room 417, Building A, Samhwan Hipex
- Seongnam-si
- South Korea
Corporate Office
- 240 Pangyoyeok-ro, Bundang-gu
- Room 417, Building A, Samhwan Hipex
- Seongnam-si
- South Korea
Bukwang Unipharma Timeline
Bukwang Unipharma Stock Performance
As of 29-Jul-2026, Bukwang Unipharma’s stock price is $5.62.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.62 | $6.05 | $5.62 - $5.62 | 26.5M | -$8.89 |
Bukwang Unipharma Financials Summary
As of 30-Jun-2026, Bukwang Unipharma has a trailing 12-month revenue of $17.5M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 24,841 | 53,919 | ||
| Revenue | 17,539 | 25,562 | 37,583 | 48,315 |
| EBITDA | (12,680) | (16,012) | (8,994) | (4,977) |
| Net Income | (16,746) | (21,656) | (15,330) | (13,887) |
| Total Assets | 50,289 | 31,830 | 50,856 | 73,273 |
| Total Debt | 3,377 | 14,884 | 16,289 | 30,535 |
Bukwang Unipharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bukwang Unipharma Patents
Bukwang Unipharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2013085152-A1 | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors | Inactive | 07-Dec-2011 | ||
| WO-2010056040-A2 | Novel erythropoietin conjugates bonded with a biocompatible polymer | Inactive | 11-Nov-2008 | ||
| WO-2010056040-A3 | Novel erythropoietin conjugates bonded with a biocompatible polymer | Inactive | 11-Nov-2008 | A61K47/30 |
Bukwang Unipharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bukwang Unipharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Bukwang Unipharma FAQs
-
When was Bukwang Unipharma founded?
Bukwang Unipharma was founded in 1956.
-
Where is Bukwang Unipharma headquartered?
Bukwang Unipharma is headquartered in Seongnam-si, South Korea.
-
What is the size of Bukwang Unipharma?
Bukwang Unipharma has 131 total employees.
-
What industry is Bukwang Unipharma in?
Bukwang Unipharma’s primary industry is Pharmaceuticals.
-
Is Bukwang Unipharma a private or public company?
Bukwang Unipharma is a Public company.
-
What is Bukwang Unipharma’s stock symbol?
The ticker symbol for Bukwang Unipharma is 080720.
-
What is the current stock price of Bukwang Unipharma?
As of 29-Jul-2026 the stock price of Bukwang Unipharma is $5.62.
-
What is Bukwang Unipharma’s current revenue?
The trailing twelve month revenue for Bukwang Unipharma is $17.5M.
-
What is Bukwang Unipharma’s annual earnings per share (EPS)?
Bukwang Unipharma’s EPS for 12 months was -$8.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
